WO1990002186A1 - Production of bluetongue virus non-structural proteins using a baculovirus expression vector - Google Patents
Production of bluetongue virus non-structural proteins using a baculovirus expression vector Download PDFInfo
- Publication number
- WO1990002186A1 WO1990002186A1 PCT/GB1989/000939 GB8900939W WO9002186A1 WO 1990002186 A1 WO1990002186 A1 WO 1990002186A1 GB 8900939 W GB8900939 W GB 8900939W WO 9002186 A1 WO9002186 A1 WO 9002186A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- btv
- protein
- polypeptide
- cells
- infected
- Prior art date
Links
- 241000120506 Bluetongue virus Species 0.000 title claims abstract description 60
- 101710172711 Structural protein Proteins 0.000 title claims abstract description 12
- 241000701447 unidentified baculovirus Species 0.000 title claims description 29
- 239000013604 expression vector Substances 0.000 title claims description 9
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 241000238631 Hexapoda Species 0.000 claims abstract description 24
- 208000003836 bluetongue Diseases 0.000 claims abstract description 5
- 210000004027 cell Anatomy 0.000 claims description 78
- 108090000623 proteins and genes Proteins 0.000 claims description 47
- 102000004169 proteins and genes Human genes 0.000 claims description 36
- 210000005239 tubule Anatomy 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 101710182846 Polyhedrin Proteins 0.000 claims description 8
- 230000000890 antigenic effect Effects 0.000 claims description 6
- 230000000877 morphologic effect Effects 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 30
- 241000700605 Viruses Species 0.000 description 28
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 239000000284 extract Substances 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 239000012634 fragment Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 239000013598 vector Substances 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 9
- 241001494479 Pecora Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 7
- 101150036211 M6 gene Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 241000256251 Spodoptera frugiperda Species 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000000635 electron micrograph Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 108091026890 Coding region Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101710081079 Minor spike protein H Proteins 0.000 description 3
- 101150067196 NSI gene Proteins 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 3
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241001493067 Bluetongue virus 2 Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241001545522 Aguacate virus Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000134316 Culicoides <genus> Species 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000120510 Epizootic hemorrhagic disease virus Species 0.000 description 1
- 241001288713 Escherichia coli MC1061 Species 0.000 description 1
- 101000782432 Eumenes pomiformis Venom peptide 5 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241000702247 Reoviridae Species 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000256248 Spodoptera Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 210000000234 capsid Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 229910001651 emery Inorganic materials 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- DBPYGJOORSXBMI-UHFFFAOYSA-N trinaphthalen-1-yl phosphate Chemical compound C1=CC=C2C(OP(OC=3C4=CC=CC=C4C=CC=3)(OC=3C4=CC=CC=C4C=CC=3)=O)=CC=CC2=C1 DBPYGJOORSXBMI-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- This invention relates to a process for producing bluetongue virus proteins.
- Bluetongue virus is the prototype virus of the Qvbi ⁇ iTus genus (Reoviridae family) . It is vectored to vertebrates by Culicoides species and causes disease in certain ruminants, notably sheep.
- the genome of BTV consists of 10 unique double-stranded (ds) RNA molecules, each believed to code for a single polypeptide product. (Gorman et al. , 1981; Sanger and Mertens, 1983).
- the ten dsRNA species are contained in an inner core structure that contains five types of proteins, two that are major (VP3 and VP7) and three that are minor components (VPl, VP4 and VP6) .
- the core is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5, to give a complete virion particle with a diameter of approximately 69 nm.
- non-structural proteins In addition to the above-mentioned structural proteins, three non-structural proteins (NSI, NS2 and NS3) appear in BTV infected cells. Their function in the replication or morphogenesis of BTV is not known. Two viral specific entities, tubules and granular inclusion bodies, are routinely obserbed in BTV infected cells (Lecatsas, 1968) . These morphological structures are attached to the intermediate filament component of the cell's cytoskeleton (Eaton, B.T. et al. , 1988) and are presumed to be involved in the virus assembly process.
- tubular structures are composed entirely of one type of polypeptide, namely the 64,000 Dalton (64 kD) NSI protein, which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
- 64,000 Dalton (64 kD) NSI protein which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
- M6 BTV dsRNA middle size segment No. 6
- a process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide.
- An example of such a polypeptide is the NSI protein of bluetongue virus.
- insects and cultured insect cells are capable of producing bluetongue virus non- structural proteins in morphological forms which resemble structures observed in bluetongue-virus infected mammalian, cells.
- BTV-NSI when produced in accordance with the invention in insect cells has been found to "self-assemble" into tubules which are similar to tubules observed in bluetongue virus infected sheep cells.
- the expression vectors used in the method of the invention may comprise a recombinant baculovirus having a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein.
- Such recombinant baculoviruses may include promoter systems native to naturally occurring baculoviruses, for example the so-called “polyhedrin” promoter, or they may include other promoter systems capable of directing expression of polypeptide in transformed insect or cultured insect cells.
- Especially suitable cultured insect cells are those of Spodoptera f_vugipe ⁇ da.
- antigenic form as used herein to refer to a protein is meant a protein which is capable of exhibiting an antigenic property of a native bluetongue virus protein, e.g. the capability of binding to an antibody to said protein.
- BTV serotype 10 (BTV-10) NSI gene product using an expression system based on recombinant baculoviruses is illustrated by the following Example.
- the expressed protein has been shown to be similar in size and antigenic properties to the authentic BTV NSI protein. It reacts with BTV ' antibody and forms numerous tubular structures in the cytoplasm of the infected insect cells. The tubular structures have been purified to homogeneity from infected cell extracts. Further the expressed polypeptide has been used to identify antibodies to five United States BTV serotypes in infected sheep sera, indicating the potential of the expressed protein as a group reactive antigen in the diagnosis of BTV infections.
- Example the BTV-10 M6 gene product is expressed in an insect baculovirus expression vector derived from AcNV.
- A. Viruses and cells United States prototype BTV-10 was plaque cloned using monolayers of BHK-21 cells. The viral dsRNA was purified as described by Yamaguchi et al. (1988) and the 10 individual RNA segments separated and isolated as described previously (Purdy et al. , 1984). AcNPV and recombinant baculovirus stocks were grown and assayed in confluent monolayers of S. fvugipe ⁇ da cells in medium containing 10 fetal calf serum according to the procedures described by Brown and Faulkner (1977) • Occasionally virus stocks were made using spinner cultures of these insect cells.
- B DNA cloning of the BTV10-M6 RNA.
- Polyadenylation of BTV-10 dsRNA and synthesis of cDNA copies of the polyadenylated M6 RNA using an oligo(dT) 1 _ 1 o primer were undertaken as described previously (Purdy et al. , 1984).
- the RNA templates were removed by treatment with 0.5 M K0H and double-stranded DNA generated by self-annealing. The products were repaired using the Klenow large fragment of DNA polymerase, followed by 3' tailing with dC and annealing to Pstl-cut, dG-tailed, pBR322 plasmid DNA (Maniatis et al. , 1982).
- RNA gel electrophoresis blotting and hybridization.
- Purified BTV-10 RNA was resolved on an agarose gel, blotted onto a Genescreen membrane (New England Nuclear, Boston MA) and hybridized to nick- translated cloned DNA by procedures described previously (Purdy et al. , 1984).
- Plasmid DNA manipulations were carried out following the procedures described by Maniatis and associates (Maniatis et al. , 1982) . Restriction enzymes, T4 DNA ligase and the Klenow large fragment of DNA polymerase, were purchased from New England Biolabs, Inc. (Beverly, MA) . Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (FGR) .
- S. fvugipevda cells were transfected with mixtures of infectious AcNPV DNA and DNA obtained from plasmid pAcBTV 10-6. Recombinant viruses were obtained as described previously (Inumaru and Roy, 1987) . One of the derived recombinant viruses was designated AcBTV 10-6.
- glycerol, 5% ⁇ -mercaptoethanol, 62.5 mM Tris-HCl, 0.01 bromophenol blue, pH 6.8) were added to each sample and the mixture heated at 100°C for 10 min.
- Proteins were analysed by electrophoresis in a 10-30$ linear gradient polyacrylamide gel in the presence of SDS (SDS-PAGE) as described by Laemmli (1970) . After electrophoresis, the gel was stained with 0.25% Coomassie brilliant blue.
- the membrane was soaked for 1 hr at room temperature in anti-rabbit IgG-goat IgG-alkaline phosphatase conjugate (Sigma Chemical Co.), also diluted in blocking buffer. After further washing with PBST, bound antibodies were detected by incubating using Fast BB salt and a-Naphthyl phosphate (Sigma Chemical Co.) as substrate.
- PBST PBS
- a solid phase indirect micro-ELISA was used to demonstrate the reactivity of recombinant AcBTV 10-6 antigen with various polyclonal BTV antisera.
- S. fs gipexda cells infected 2 hr previously with recombinant AcBTV 10-6 virus (see above) were collected and subjected to freezing and thawing followed by low speed centrifugation to remove cellular debris.
- the supernatant was diluted (1:10- to 1:10,000-fold) with sodium carbonate buffer (15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)-
- sodium carbonate buffer 15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)
- a 96-well polyvinylchloride microplate (Flow Laboratories) was coated overnight at 4xC with 50fl of the diluted antigen.
- the plate was washed three times between each step of the following protocol by flooding the wells of the plate with PBST buffer.
- the antigen-coated microplate was washed and blocked with blocking solution for 3 hr at room temperature.
- BTV antisera were diluted (1:100- to 1:12,800-fold) in blocking solution and 50 ⁇ l of diluted sera were added to each well.
- Cells were infected with the AcBTV 10-6 recombinant baculovirus and the infected cells harvested 4 or 5 days post-infection. The cells were recovered, washed twice with PBS and resuspended in 10 mM Tris-HCl (pH 7-4) and disrupted by sonication. The resulting cell extract was loaded oh a 10% to 50 (wt/v) sucrose gradient in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and centrifuged at 40,000 rpm for 3 hr using an SW4l rotor. After centrifugation, the gradient was fractionated and a portion of each fraction was subjected to gel electrophoresis. The peak fractions containing NSI protein were pooled and pelleted by centrifugation for 2 hr at 40,000 rpm. The pellet was resuspended in 10 mM Tris HC1 buffer (pH 7.4).
- a plasmid (pBTV10-6) containing the complete BTV-10 M6 sequence was constructed from two overlapping clones as described above (Fig. 2) .
- the restriction enzyme M ⁇ el was used to isolate the entire coding region of the M6 DNA (including 1 bases upstream from the ATG initiation codon and 59 bases downstream from the TAG stop codon) and the DNA used to prepare a recombinant baculovirus transfer vector.
- the 60 kD protein was NSI
- a sample of the AcBTV 10-6 infected cell extract was electrophoresed, transferred onto a Durapore membrane and subjected to Western analyses using anti-BTV-10 sera as described in Methods.
- the 60 kD protein (lane c) was identified by the alkaline phosphatase conjugate detection procedure.
- tubules of various lengths were evident. In cross-section, they exhibited a diameter of ca 60 nm. Many of the tubules appeared to contain ribosome-like particles (Fig. 5. R arrowheads). Both the structures and arrangement of the tubules were comparable to the tubular structures reported by others in BTV infected BHK-21 cells (Huismans and Els, 1979). As expected, polyhedra were only evident in the AcNPV infected cells (Fig. 5. P arrowheads).
- Fibrous structures were observed both in AcNPV and in the recombinant virus infected cells (Fig. 5) • In the latter, the tubules appeared to be aligned along the edges of bundles of the fibrous material (Fig. 5c and d) . Both the tubules and the fiberous structures were randomly oriented with respect to one another. In some cells bundles of fibers were seen in both the nucleus and the cytoplasm (Fig. 5e, f) , with tubules mostly, but not exclusively associated with the cytoplasmic fibers. Fewer tubules were seen in the nuclei (Fig. f)• Whether these tubules were formed in the nucleus, or occurred there because the cell was in the terminal stage of infection, is not known.
- Recombinant virus infected cell extracts were absorbed to microtiter plates (representing some 50 ng of NSI protein per well) and incubated with either polyclonal BTV-2, or BTV-10, or BTV-11, or BTV-13, or BTV-17 sheep antisera, or with normal sheep serum as a control.
- the derived antigen-antibody complexes were detected by incubating with anti-sheep-alkaline phosphatase conjugates followed by the addition of an enzyme substrate.
- Fig. 7 all five BTV antisera reacted with the recombinant antigen in proportion to the end point titer of the antisera. No reaction was detected with the normal sheep serum. No reactivity was obtained when each of the BTV antisera was tested with AcNPVinfected cell extracts.
- NSI is the major viral protein synthesized in BTV-infected cells and is a major constituent of the tubules which are observed in such cells. (Huismans and Els, 1979). It has now unexpectedly been found that baculovirus expressed NSI protein also form tubules in insect cells. The two overlapping clones (#14 and 39) were used to construct a plasmid containing the complete gene (pBTV 10-6) . A recombinant baculovirus was prepared with the NSI gene sequences under the control of the AcNPV polyhedrin promoter. The data herein shows that the BTV NSI protein is expressed to a high level in insect cells infected with this recombinant baculovirus.
- NSI, NS2 and NS3 can be used as group specific probes to detect the presence of bluetongue virus (all 24 serotypes); Ritter and Roy, 1988.
- BTV 10 NSI antigen can be used to detect antibodies to the US strains (BTV-2, BTV-10, BTV-11, BTV-14 and BTV-17) ; Urakawa and Roy, 1988.
- a culture of AcNPV-BTV-10 has been deposited at the European Collection of Animal Cell Cultures (ECACC) on 10th August 1989 under Accession No. 89081017.
- Fig. 1 Strategy used to determine the sequences of cDNA clones of the BTV- 10 M6 gene. The distance and directions in which individual strands of two overlapping clones were sequenced are shown by the solid arrows. Restriction enzyme sites used are as follows: Ma, Mael; Hd, Hind l; R, HinfI; D, DdeI; Pv,PuuI; Ms, spI.
- FIG. 2 Schematic diagram of the construction of the transfer vector pAcBTVlO-6.
- a pBR332-based plasmid (pBTV 10-6) containing the entire coding region of the BTV-10 M6 DNA was constructed from two overlapping partial clones as described in Methods.
- the complete clone (pBTV10-6) was used to construct the transfer vector (pAcBTVlO-6) as described in Methods.
- the sequence of the 5' insertion site was determined by the method of Maxam and Gilbert (18) using a Hin ⁇ HL restriction fragment (BTV DNA residue #296).
- Fig. 3 Hydropathic plot and distribution of cvsteine residues for the predicted M6 gene product of BTV-10.
- the plot involves a span setting of 21 amino acids.
- Fig.4 Expression of NSl protein bv recombinant baculoviruses derived from the pAcBTV10-6 transfer vector.
- S. frugiperda cells were infected with recombinant (c) or wild type AcNPV (b). Proteins were recovered at 72 hr post-infection and an aliquot of each sample was resolved by gel electrophoresis. Uninfected cells were treated similarly (a). The resolved protein bands were either detected by staining with Coomassie brilliant blue (A), or blotted onto nitrocellulose membranes and detected immunolog ⁇ cally with a ti BTV-10 serum (B) as described in Methods. The positions of NSI and the AcNPV polyhedrin protein (P) are indicated. Molecular weights (in kD) are indicated on the left.
- FIG. 5 Electron micrographs of NSl-derived tubules produced by S. frugiperda cells infected with recombinant viruses.
- S. frugiperda cells infected with AcNPV (panel a), or a recombinant virus (panels b-f) were fixed with 2% glutaraldehyde 72 hr post-infection and processed for electron microscopy as described in Methods.
- P polyhedrin
- V virus particles
- M mitochondria
- R ribosomes
- F fibrous structure
- T tubules
- N nuclear membrane.
- FIG. 6 Three-dimensional arrangement of the tubules in the infected S. frugiperda cells.
- A A series of representative virus (A-H) of the single arrays in a thin section of the tubules were photographed at 10° intervals of specimen tilt.
- B A schematic three-dimensional interpretation of the structure are represented (a, b and c).
- Fig. 7 Reaction of bluetongue antibodies to recombinant baculovirus derived antigen using indirect ELISA: Recombinant AcBTV 10-6 infected cell extracts were adsorbed to the solid phase and examined using 1:100 to 1:12800 dilutions of sheep anti-BTV-2 serum ( ⁇ e), or anti-BTV- 10 serum (o o), or anti-BTV-11 serum ( ⁇ A), or anti-BTV-13 serum ( ⁇ ⁇ ), or anti-BTV-17 serum (G ⁇ ), or with normal sheep serum (gg U).
- Fig. 8 SDS-PAGE of purified NSI protein stained with Coomassie brilliant blue: AcBTV10-6 recombinant baculovirus infected cells were disrupted and tubules were recovered by sedimenting in sucrose gradient (10-50% w/v) centrifugation as described in Methods. The peak fractions containing NSl were pooled and subjected to SDS-PAGE analysis. The proteins recovered from unpurif ⁇ ed recombinant virus infected cells (1) are compared with NSl protein purified through sucrose gradient centrifugation (2). - /S
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Bluetongue virus non-structural proteins (particularly Bluetongue NSI protein) are expressed in insect cells.
Description
PRODUCTION OF BLUETONGUE VIRUS NON-STRUCTURAL PROTEINS USING A BACULOVIRUS EXPRESSION VECTOR
This invention relates to a process for producing bluetongue virus proteins.
Bluetongue virus (BTV) is the prototype virus of the QvbiυiTus genus (Reoviridae family) . It is vectored to vertebrates by Culicoides species and causes disease in certain ruminants, notably sheep.
■ The genome of BTV consists of 10 unique double-stranded (ds) RNA molecules, each believed to code for a single polypeptide product. (Gorman et al. , 1981; Sanger and Mertens, 1983). The ten dsRNA species are contained in an inner core structure that contains five types of proteins, two that are major (VP3 and VP7) and three that are minor components (VPl, VP4 and VP6) . The core is surrounded by an outer capsid consisting of two major proteins, VP2 and VP5, to give a complete virion particle with a diameter of approximately 69 nm. In a prior patent application (EP-88301348.4-2105) there is described the production of these BTV structural proteins, particularly VP2 and VP3, in insect cells using a baculovirus expression vector. VP2 is able to elicit neutralizing antibody and VP3 can elicit group-reactive antibody and therefore these antigens may be used for diagnosis of, and as a vaccine against, BTV infection.
In addition to the above-mentioned structural proteins, three non-structural proteins (NSI, NS2 and NS3) appear in BTV infected cells. Their function in the replication or morphogenesis of BTV is not known. Two viral specific entities, tubules and granular inclusion bodies, are routinely obserbed in BTV infected cells (Lecatsas, 1968) . These morphological structures are attached to the intermediate filament component of the cell's cytoskeleton (Eaton, B.T. et al. , 1988) and are presumed to be involved in the virus assembly process. It has been shown (Huismans and Els, 1979) that the tubular structures are composed entirely of one type of polypeptide, namely the 64,000 Dalton (64 kD) NSI protein, which is the gene product of BTV dsRNA middle size segment No. 6 (M6) .
There is a need to be able to produce additional antigenically active bluetongue virus proteins by recombinant DNA technology so that antigens are available for the effective diagnosis of BTV infection and for the development of vaccines.
Following the successful expression of antigenically competant BTV structural proteins in insect cells outlined above, it has now surprisingly been found that expression systems based on insect cells can efficiently be used* to achieve expression of BTV non-structural proteins in antigenic form. Thus according to the present invention there is provided a process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide. An example of such a polypeptide is the NSI protein of bluetongue virus.
Surprisingly it has been found that insects and cultured insect cells are capable of producing bluetongue virus non- structural proteins in morphological forms which resemble structures observed in bluetongue-virus infected mammalian, cells. Thus, for example, BTV-NSI, when produced in accordance with the invention in insect cells has been found to "self-assemble" into tubules which are similar to tubules observed in bluetongue virus infected sheep cells.
Especially suitable expression vectors are those based on baculov ruses. Thus for example the expression vectors used in the method of the invention may comprise a recombinant baculovirus having a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein.
Such recombinant baculoviruses may include promoter systems native to naturally occurring baculoviruses, for example the so-called "polyhedrin" promoter, or they may include other promoter systems capable of directing expression of polypeptide in transformed insect or cultured insect cells.
Especially suitable cultured insect cells are those of Spodoptera f_vugipeτda.
By the term "antigenic form" as used herein to refer to a protein is meant a protein which is capable of exhibiting an
antigenic property of a native bluetongue virus protein, e.g. the capability of binding to an antibody to said protein.
The expression and characterisation of the BTV serotype 10 (BTV-10) NSI gene product using an expression system based on recombinant baculoviruses is illustrated by the following Example. The expressed protein has been shown to be similar in size and antigenic properties to the authentic BTV NSI protein. It reacts with BTV' antibody and forms numerous tubular structures in the cytoplasm of the infected insect cells. The tubular structures have been purified to homogeneity from infected cell extracts. Further the expressed polypeptide has been used to identify antibodies to five United States BTV serotypes in infected sheep sera, indicating the potential of the expressed protein as a group reactive antigen in the diagnosis of BTV infections.
In the Example the BTV-10 M6 gene product is expressed in an insect baculovirus expression vector derived from AcNV.
Example - Expression of BTV NSI
A. Viruses and cells. United States prototype BTV-10 was plaque cloned using monolayers of BHK-21 cells. The viral dsRNA was purified as described by Yamaguchi et al. (1988) and the 10 individual RNA segments separated and isolated as described previously (Purdy et al. , 1984). AcNPV and recombinant baculovirus stocks were grown and assayed in confluent monolayers of S. fvugipeτda cells in medium containing 10 fetal calf serum according to the procedures described by Brown and Faulkner (1977) • Occasionally virus stocks were made using spinner cultures of these insect cells.
B. DNA cloning of the BTV10-M6 RNA. Polyadenylation of BTV-10 dsRNA and synthesis of cDNA copies of the polyadenylated M6 RNA using an oligo(dT)1 _1o primer were undertaken as described previously (Purdy et al. , 1984). The RNA templates were removed by treatment with 0.5 M K0H and double-stranded DNA generated by self-annealing. The products were repaired using the Klenow large fragment of DNA polymerase, followed by 3' tailing with dC and annealing to Pstl-cut, dG-tailed, pBR322 plasmid DNA (Maniatis
et al. , 1982). After transformation, clones containing the viral sequences were recovered and screened by colony hybridization (Grunstein and Hogness, 1975)- Hinfl restriction patterns of recombinant plasmids were compared as described previously (Purdy et al. , 1984).
C. RNA gel electrophoresis, blotting and hybridization. Purified BTV-10 RNA was resolved on an agarose gel, blotted onto a Genescreen membrane (New England Nuclear, Boston MA) and hybridized to nick- translated cloned DNA by procedures described previously (Purdy et al. , 1984).
D. Sequencing of BTV M6 DNA clones. Sequencing was carried out end-labeled, strand-separated, restriction fragments of plasmid DNA containing the viral M6 DNA using the Maxam and Gilbert method (Maxam and Gilbert, I98O) .
E. DNA manipulations and construction of a complete BTV M6 gene.
Plasmid DNA manipulations were carried out following the procedures described by Maniatis and associates (Maniatis et al. , 1982) . Restriction enzymes, T4 DNA ligase and the Klenow large fragment of DNA polymerase, were purchased from New England Biolabs, Inc. (Beverly, MA) . Calf intestine alkaline phosphatase was obtained from Boehringer Mannheim (FGR) .
Two M6 DNA clones representing nucleotides 1-1100 (#14) and 7OO-I769 (#39) were sequenced as reported previously (15, see Fig. 1) . The construction of plasmid pBTV 10-6 representing the complete M6 DNA is illustrated in Fig. 2. Clone #14 was initially recloned in the opposite orientation into the Pstl site of pBR322. The derived clone (#14-9) was then digested with Pvul and a fragment of DNA containing M6 residues I-898 was recovered and dephosphorylated (Fig. 2) . A Puyl derived fragment was obtained from clone #39 containing M6 residues 899-1769- The two fragments were ligated together. After transformation of Escherichia coli MC1061 cells and the selection of drug-resistant colonies followed by colony
hybridization screening (Grunstein and Hogness, 1975) using the nick-translated products of M6 DNA derived from clones #14 and #39. clone pBTV 10-6 was identified and confirmed by the appropriate restriction enzyme and sequence analyses to contain BTV-10 M6 residues I-I769.
F. Construction of a recombinant baculovirus transfer vector. A
1746 base-pair DNA fragment containing the entire coding region of the BTV-10 M6 DNA, was excised from plasmid pBTV 10-6 with Kael, repaired with the Klenow large fragment of DNA polymerase, then cloned into the BαmHI site of the baculovirus transfer vector pAcYMl (Matsuura et al. , 19δ7) • The derived recombinant transfer vector (designated pAcBTV 10-6, Fig. 2) was characterised by restriction enzyme and sequence analyses (Maxam and Gilbert, 198O) and was shown to have the viral insert in the correct orientation for expression directed by the AcNPV polyhedrin promoter.
G. Transfection and selection of recombinant viruses. To obtain recombinant viruses that would express the BTV M6 gene,
S. fvugipevda cells were transfected with mixtures of infectious AcNPV DNA and DNA obtained from plasmid pAcBTV 10-6. Recombinant viruses were obtained as described previously (Inumaru and Roy, 1987) . One of the derived recombinant viruses was designated AcBTV 10-6.
H. Analysis of infected cell polypeptides by polyacrylamide gel electrophoresis♦ S. fvugipevda cells in 35 πim tissue culture dishes were infected with viruses at a multiplicity of 10 PFU/cell and the cells incubated at 28°C for 3 days. At the end of the incubation period, cells were rinsed three times with phosphate buffered saline (PBS) and resuspended in 100 μl of 10 mM Tris-HCl buffer (pH 7.4). 50 μl of protein dissociation buffer (2.3 SDS, 10/1. glycerol, 5% β-mercaptoethanol, 62.5 mM Tris-HCl, 0.01 bromophenol blue, pH 6.8) were added to each sample and the mixture heated at 100°C for 10 min. Proteins were analysed by electrophoresis in a 10-30$ linear gradient polyacrylamide gel in
the presence of SDS (SDS-PAGE) as described by Laemmli (1970) . After electrophoresis, the gel was stained with 0.25% Coomassie brilliant blue.
I. Timminoblotting analyses. After SDS-PAGE, cellular proteins were transferred electrophoretically for 3 hr at 0.8 mA/cm (Kyhse-Anderson, 1984) into a Durapore membrane (Millipore Corp.) using a semi-dry electroblotter (Sartoblot II Sartorius Corp). After transfer, the membrane was soaked overnight at 4xC in blocking buffer (5% skimmed milk, 0.05 Tween 20 in PBS, pH 7-4). The membrane was then treated for 2 hr with rabbit anti-BTV-10 serum diluted 1000-fold in blocking buffer. Following a second wash with 0.05% Tween-20 in PBS (PBST) , the membrane was soaked for 1 hr at room temperature in anti-rabbit IgG-goat IgG-alkaline phosphatase conjugate (Sigma Chemical Co.), also diluted in blocking buffer. After further washing with PBST, bound antibodies were detected by incubating using Fast BB salt and a-Naphthyl phosphate (Sigma Chemical Co.) as substrate.
J. Electron micrographs of infected cells. S. fvugipeτda cells were infected with recombinant baculoviruses at a multiplicity of 10 PFU/cell and incubated at 2δxC for 3 days. The cells were washed with PBS, fixed with glutaraldehyde and treated with osmic acid. Cell sections were observed in a JE0L electron microscope.
K. ELISA for the detection of antibody to BTV NSI polypeptide using recombinant baculovirus derived antigens. A solid phase indirect micro-ELISA was used to demonstrate the reactivity of recombinant AcBTV 10-6 antigen with various polyclonal BTV antisera. S. fs gipexda cells infected 2 hr previously with recombinant AcBTV 10-6 virus (see above) were collected and subjected to freezing and thawing followed by low speed centrifugation to remove cellular debris. The supernatant was diluted (1:10- to 1:10,000-fold) with sodium carbonate buffer (15 mM Na-CO-, 36 mM NaHC0_, pH 9-6)- A 96-well polyvinylchloride microplate (Flow Laboratories) was coated overnight at 4xC with 50fl of the diluted antigen. The plate was washed three times between each step of the following protocol by flooding the wells of the plate with PBST
buffer. The antigen-coated microplate was washed and blocked with blocking solution for 3 hr at room temperature. BTV antisera were diluted (1:100- to 1:12,800-fold) in blocking solution and 50μl of diluted sera were added to each well. After 2 hr of incubation the plate was washed and 100 μl of a 1:1000 dilution of anti-sheep IgG-alkaline phosphatase conjugate (Sigma Chemicals) was added to each well followed by 2 hr incubation at 28°C. The substrate, p-nitrophenylphosphate (Sigma Chemicals) solution (0.1% w/v final concentration), was added for 30 min, or less. After suitable colour development at room temperature the reaction was stopped by addition of 0.3 M NaOH. The optical density was read using a multichannel spectrophotometer (Microelisa Autoreader, MR 58O, Dynatech Co.) at a wavelength of 405 nm.
L. Purification of tubular stuctures by gradient centrifugation.
Cells were infected with the AcBTV 10-6 recombinant baculovirus and the infected cells harvested 4 or 5 days post-infection. The cells were recovered, washed twice with PBS and resuspended in 10 mM Tris-HCl (pH 7-4) and disrupted by sonication. The resulting cell extract was loaded oh a 10% to 50 (wt/v) sucrose gradient in TE buffer (10 mM Tris-HCl, 0.1 mM EDTA, pH 7.4) and centrifuged at 40,000 rpm for 3 hr using an SW4l rotor. After centrifugation, the gradient was fractionated and a portion of each fraction was subjected to gel electrophoresis. The peak fractions containing NSI protein were pooled and pelleted by centrifugation for 2 hr at 40,000 rpm. The pellet was resuspended in 10 mM Tris HC1 buffer (pH 7.4).
The results achieved in the above Example is apparent from the following discussion.
1. Nucleotide sequence determination of the BTV-10 M6 DNA and its predicted gene product. The sequence of the cloned M6 gene was determined on strand separated, end-labeled, restriction DNA fragments obtained from two overlapping clones (#14 and #39) using the strategy shown in Fig. 1. The distance each DNA strand was sequenced is indicated by an arrow. The complete nucleotide sequence of these DNA clones has been reported elsewhere (Lee and Roy, 1987) •
Approximately 90% of the gene was sequenced in both directions. Excluding the homopolymeric tails, the gene is 1769 nucleotides long with a single open reading frame beginning with an RNA AUG triplet at residues 35-37. This open reading frame terminates with a UAG translation termination codon at residues #1691-1693 (Lee and Roy, 1987) . Based on the sequence data, the BTV-10 M6 RNA codes for a primary gene product composed of 5 amino acids with an estimated size of 64,445 Daltons (Table- 1) and an overall net positive charge of +2 at neutral pH. The protein has 16 cysteine residues (3%) • The hydropathic profile of the protein (Fig. 3) indicates that it contains several regions of hydrophobic amino acids (regions above the central line) throughout the molecule, particularly in the carboxy terminal half.
2. Construction of baculovirus recombinants. A plasmid (pBTV10-6) containing the complete BTV-10 M6 sequence was constructed from two overlapping clones as described above (Fig. 2) . To remove unnecessary sequences (such as the homopolymeric tails, the restriction enzyme Mαel was used to isolate the entire coding region of the M6 DNA (including 1 bases upstream from the ATG initiation codon and 59 bases downstream from the TAG stop codon) and the DNA used to prepare a recombinant baculovirus transfer vector.
Previous studies have demonstrated that for many genes the highest baculovirus expression levels are obtained with the transfer vector pAcYMl (Emery and Bishop, 1987 Matsuura et al. , 1987; Schmaljohn et al. , 1988) . This vector contains the entire upstream sequence of the AcNPV polyhedrin gene, including the A of the initiating ATG codon. The coding sequences of the BTV-10 M6 DNA were therefore inserted into the transfer vector pAcYMl as described above (Fig. 2) . The derived recombinant (pAcBTV 10-6) was analysed by restriction endonuclease digestion and the junction sequences determined (Fig. 3)« S- fTugipe da cells were transfected with mixtures of AcNPV DNA and the plasmid DNA pAcBTV 10-6. Recombinant viruses (e.g., AcBTV 10-6) were identified by their polyhedrin- negative plaque phenotypes and plaque purified three times using monolayers of S. frugiperda cells.
3. Expression of bluetongue virus NSI protein. In order to demonstrate that BTV-10 NSI protein was synthesized in recombinant baculovirus infected cells, protein extracts were prepared from insect cells infected with the recombinant virus AcBTV 10-6 as described above. Extracts were also made from AcNPV- and mock-infected cells. A sample of each preparation was subjected to SDS-PAGE and the resolved proteins stained with Coomassie brilliant blue. As shown in Fig. 4A (lane c) , the recombinant virus synthesized a protein with a molecular size of ca 60 kD, in agreement with the estimated size of the BTV-10 NSI protein (see Table 1). Based on comparisons of stained gels containing known quantities of bovine serum albumin, the amount of this protein was estimated to be of the order of 1 mg per 2 x 10 infected cells, i.e., as high as the polyhedrin protein made in AcNPV infected cells (compare Fig. 4A, lanes b and c) .
In order to confirm that the 60 kD protein was NSI, a sample of the AcBTV 10-6 infected cell extract was electrophoresed, transferred onto a Durapore membrane and subjected to Western analyses using anti-BTV-10 sera as described in Methods. As shown in Fig. 4B, the 60 kD protein (lane c) was identified by the alkaline phosphatase conjugate detection procedure.
4. Electron microscope analysis of cells infected with recombinants that express the BTV NSI protein. It has been postulated that the NSI protein of BTV is the sole component of the tubular structures identified in BTV-infected cells (Huismans and Els, 1979). An examination was therefore undertaken of electron micrographs of S. fvugiperda cells infected with the AcBTV 10-6 recombinant virus, or with wild-type AcNPV. As shown in Fig. 5b and in contrast to AcNPV infected cells (Fig. 5a) , numerous tubular structures were evident only in the cytoplasm in the recombinant virus infected cells (Fig. 5. T arrowheads). In the thin section tubules of various lengths were evident. In cross-section, they exhibited a diameter of ca 60 nm. Many of the tubules appeared to contain ribosome-like particles (Fig. 5. R arrowheads). Both the structures and arrangement of the tubules were comparable to the tubular structures reported by others in BTV infected BHK-21 cells
(Huismans and Els, 1979). As expected, polyhedra were only evident in the AcNPV infected cells (Fig. 5. P arrowheads).
Fibrous structures were observed both in AcNPV and in the recombinant virus infected cells (Fig. 5) • In the latter, the tubules appeared to be aligned along the edges of bundles of the fibrous material (Fig. 5c and d) . Both the tubules and the fiberous structures were randomly oriented with respect to one another. In some cells bundles of fibers were seen in both the nucleus and the cytoplasm (Fig. 5e, f) , with tubules mostly, but not exclusively associated with the cytoplasmic fibers. Fewer tubules were seen in the nuclei (Fig. f)• Whether these tubules were formed in the nucleus, or occurred there because the cell was in the terminal stage of infection, is not known.
In order to assess the possible three-dimensional arrangement of the tubules in the infected S. f_v gipeτda cells, single arrays in thin sections were examined in a Jeol electron microscope equipped with a tilting stage. A series of photographs was taken at 10° intervals of specimen tilt. It was apparent from Fig. 6A that the circular particles visualised in the lower left of the picture taken at a -40° tilt transformed to oblique particules at a -30° tilt and were progressively observed as longitudinal tubules at -10° to the +50° tilting stages. Similar transformations were observed for other arrays of tubules in the section (see Fig. 6A) . A schematic three-dimensional interpretation of the structures is provided in Fig. 6B.
5- ET.TSA assays using recombinant virus derived NSI to identify bluetongue antibodies. Since the NSI gene (M6) of BTV-10 has been shown to be highly conserved among 20 BTV serotypes (Huismans and Cloete, 1987; Ritter and Roy, 1988) , the question of whether the NSI protein produced by the recombinant baculovirus reacted with homologous and heterologous BTV antisera was investigated using an ELISA test. Recombinant virus infected cell extracts were absorbed to microtiter plates (representing some 50 ng of NSI protein per well) and incubated with either polyclonal BTV-2, or BTV-10, or BTV-11, or BTV-13, or BTV-17 sheep antisera, or with normal sheep serum as a control. The derived antigen-antibody complexes were
detected by incubating with anti-sheep-alkaline phosphatase conjugates followed by the addition of an enzyme substrate. As shown in Fig. 7. all five BTV antisera reacted with the recombinant antigen in proportion to the end point titer of the antisera. No reaction was detected with the normal sheep serum. No reactivity was obtained when each of the BTV antisera was tested with AcNPVinfected cell extracts.
6. Purified tubules recovered from recombinant virus infected insect cells. In order to purify the tubular structures, infected cell extracts were prepared and subjected to sucrose gradient centrifugation. A portion of each fraction was analysed by SDS-PAGE and peak fractions containing NSI protein were pooled and pelleted. As shown in Fig. 8, the recovered protein, stained with Coomassie brilliant blue, was effectively purified by this one-step procedure. Electron micrographs revealed that the preparation was composed of tubules with little evidence of cytoplasmic or other contamination.
SUMMARY
Two overlapping cDNA clones representing segment M6 of BTV-10 have been used to determine the complete sequence of the viral RNA. The sequence was deduced to be 1,769 base-pairs long, in good agreement with the 1.8 Kb length calculated by agarose gel electrophoresis. The single open reading frame of significant length is initiated with an AUG at residues 35"37 and codes for a protein of some 552 amino acids. The predicted NSI protein coded by the M6 RNA has a size of 64,445 Da. slightly larger than the size estimated by Huismans (1979). or- estimated the electrophoretic mobility of the protein observed in gels by comparison with protein markers (Fig. 4) . Computer analyses of the predicted amino acid sequences of the protein indicated that the molecule has domains of hydrophobic amino acids, particularly near the carboxy terminus, and contains many cysteine residues.
NSI is the major viral protein synthesized in BTV-infected cells and is a major constituent of the tubules which are observed in such cells. (Huismans and Els, 1979). It has now unexpectedly been found that baculovirus expressed NSI protein also form tubules
in insect cells. The two overlapping clones (#14 and 39) were used to construct a plasmid containing the complete gene (pBTV 10-6) . A recombinant baculovirus was prepared with the NSI gene sequences under the control of the AcNPV polyhedrin promoter. The data herein shows that the BTV NSI protein is expressed to a high level in insect cells infected with this recombinant baculovirus. From stained preparation of cell extracts it was estimated that the amount of NSI present in cells infected at high multiplicity with the recombinant virus was ca 50% of the total stainable protein in the cell extract prepared at the end of the infection course. It has further been demonstrated that the recombinant baculovirus makes tubular structures in insect cells similar to those reported in BTV infected cell cultures (Huismans and Els, 1979). The tubules have been purified and demonstrated to be composed of NSI protein.
Previously it has been reported that the DNA probe representing the BTV M6 RNA hybridized with the corresponding RNA segments of 20 out of 20 BTV serotypes tested, indicating that the gene (and gene product) is highly conserved (Ritter and Roy, 1988) .
Moreover, unlike similar data obtained with genes representing the viral structural proteins, no hybridization was obtained with the corresponding segments of two epizootic haemorrhagic disease virus serotypes indicating that NSI genes are perhaps conserved only by BTV serotypes. If correct, then NSI antigen would be valuable as a reagent for the diagnosis of bluetongue virus infections. In order to investigate the value of the expressed NSI protein as a diagnostic reagent, recombinant virus derived NSI protein was applied in an ELISA test with five available US BTV antisera. The data obtained indicates that the genetically engineered NSI antigen is suitable for identifying all the US BTV serotypes.
The genes for NSI, NS2 and NS3 can be used as group specific probes to detect the presence of bluetongue virus (all 24 serotypes); Ritter and Roy, 1988.
BTV 10 NSI antigen can be used to detect antibodies to the US strains (BTV-2, BTV-10, BTV-11, BTV-14 and BTV-17) ; Urakawa and Roy, 1988.
DEPOSITS
A culture of AcNPV-BTV-10 (NSI) has been deposited at the European Collection of Animal Cell Cultures (ECACC) on 10th August 1989 under Accession No. 89081017.
LITERATURE CITED
1. Borden, E.C., R.E. Shope, and F.A. Murphy. 1971. Physicocheinical and morphological relationships of some arthropod-borne viruses to bluetongue virus - a new taxonomic group. Physico-chemical and serological studiesl J. Gen. Virol. 13:361-271.
2. Brown, M. and P. Faulkner. 1977. A plaque assay for nucler polyhedrosis viruses using a solid overlay. J. Gen. Virol. 36:361-364.
3. Eaton, B.T., A.D. Hyatt and J.R White. 1988. Localization of the nonstructural protein NSl . in bluetongue virus-infected cells and its presence in virus particles. Virology 163:527-537.
4. Emery, V.C. and D.H.L. Bishop. 1987. The development of multiple expression vectors for high level synthesis of eukaryotic proteins: expression of LCMV-N and AcNPV polyhedrin protein by a recombinant baculovirus. Protein Engineering 1 :359-366.
5. Grunstein, J.M. and D.S. Hogness. 1975. Colony hybridization: a method for the isolation of cloned DNAs that contain a specific gene. Proc. Natl. Acad. Sci. USA 72:3961-3965.
6. Huismans, H. 1979. Protein synthesis in bluetongue virus-infected cells. Virology 92:385-396.
7. Huismans, H. and M. Cloete. 1987. A comparison of different cloned bluetongue virus genome segments as probes for the detection of virus- specified RNA. Virology 15S.373-380.
- -
8. Huismans, H. and H.J. Els. 1979. Characterization of the tubules associated with the replication of three different orbiviruses. Virology 92:387-406.
9. Inumaru, S. and P. Roy. 1987. Production and characterization of the neutralization antigen VP2 of bluetongue virus serotype 10. Virology 157:472-479.
10. Kyhse-Andersen, J. (1984). Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of protein from polyacrylamide to nitrocellulose. J. Biochem. and Biophys. methods 10:203-
11. Kyte, T. and R.F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
12. Laemmli, U.K. 1970. Cleavage of the structural proteins during assembly of the head of bacteriophage T4. Nature (London) 227:680-685.
13. Lecatsas, G. 1968. Electron microscope study of the formation of bluetongue virus. Onderstepoort J. Vet. Res.35:139-150.
14. Lecatsas, G. and B.M. Gorman. 1972. Visualization of the extra capsid coat in certain bluetongue-type viruses. Onderspoort J. Vet. Res. 39:193- 196.
15. Lee, J. and P. Roy, 1987. Complete sequence of the NSl gene (M6 RNA) of US bluetongue virus serotype 10. Nucleic Acids Research 15:7207.
16. Maniatis, T., E.F. Fritsche and J. Sambrook. 1982. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Harbor Laboratory.
17. Matsuura, Y., R.D. Possee, H.A. Overton and D.H.L Bishop. 1987. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J. Gen. Virol. 6S:1233-1250.
18. Maxam, A. and W. Gilbert. 1980. Sequencing end-labelled DNA with base-specific chemical cleavages. In L. Grossman and K. Moldave, (ed.)"Methods in Enzymology" Vol. 65, pp. 499-560. Academic Press, New York.
19. Purdy, M., Petre, J. and P. Roy. 1984. Cloning the bluetongue virus L3 gene. J. Virol. 51:754-759.
20. Ritter, D.G. and P. Roy. 1988. Genetic relationships of bluetongue virus serotypes isolated from different parts of the world. Virus Research 11: (in press).
21. Schmaljohn, C.S., K. Sugiyama, A.L. Schmaljohn and D.H.L. Bishop. 1988. Baculovirus expression of the small genome segment of Hantaan virus and potential use of the expressed nucleocapsid protein as a diagnostic antigen. J. gen. Virol. 69:777-786.
22. Yamaguchi, S., A. Fukusho and P. Roy. 1988. Complete sequence of neutralization protein VP2 of the recent US isolate bluetongue virus serotype 2: its relationship with VP2 species of other US serotypes. Virus Research 11: (in press).
23. Ritter, D.G. and P. Roy. 1988. Virus, Vol. 11, pages 33 to 47.
24. Urakawa and P. Roy. 1988. J. Virology, Vol. 62, pages 3919 to 3927.
FIGURE LEGENDS
Fig. 1 Strategy used to determine the sequences of cDNA clones of the BTV- 10 M6 gene. The distance and directions in which individual strands of two overlapping clones were sequenced are shown by the solid arrows. Restriction enzyme sites used are as follows: Ma, Mael; Hd, Hind l; R, HinfI; D, DdeI; Pv,PuuI; Ms, spI.
Fig. 2 Schematic diagram of the construction of the transfer vector pAcBTVlO-6. A pBR332-based plasmid (pBTV 10-6) containing the entire coding region of the BTV-10 M6 DNA was constructed from two overlapping partial clones as described in Methods. The complete clone (pBTV10-6) was used to construct the transfer vector (pAcBTVlO-6) as described in Methods. The sequence of the 5' insertion site was determined by the method of Maxam and Gilbert (18) using a HinάHL restriction fragment (BTV DNA residue #296).
Fig. 3 Hydropathic plot and distribution of cvsteine residues for the predicted M6 gene product of BTV-10. The regions of the protein that have a net hydrophobicity (areas above the center line), or hydrophilicity (areas below the center line), as well as the distribution of cvsteine residues (vertical bars), are displayed (11). The plot involves a span setting of 21 amino acids.
Fig.4 Expression of NSl protein bv recombinant baculoviruses derived from the pAcBTV10-6 transfer vector. S. frugiperda cells were infected with recombinant (c) or wild type AcNPV (b). Proteins were recovered at 72 hr post-infection and an aliquot of each sample was resolved by gel electrophoresis. Uninfected cells were treated similarly (a). The resolved protein bands were either detected by staining with Coomassie brilliant blue (A), or blotted onto nitrocellulose membranes and detected immunologϊcally with a ti BTV-10 serum (B) as described
in Methods. The positions of NSI and the AcNPV polyhedrin protein (P) are indicated. Molecular weights (in kD) are indicated on the left.
Fig. 5 Electron micrographs of NSl-derived tubules produced by S. frugiperda cells infected with recombinant viruses. S. frugiperda cells infected with AcNPV (panel a), or a recombinant virus (panels b-f) were fixed with 2% glutaraldehyde 72 hr post-infection and processed for electron microscopy as described in Methods. P, polyhedrin; V, virus particles; M, mitochondria; R, ribosomes; F, fibrous structure; T, tubules; N, nuclear membrane.
Fig. 6 Three-dimensional arrangement of the tubules in the infected S. frugiperda cells. (A) A series of representative virus (A-H) of the single arrays in a thin section of the tubules were photographed at 10° intervals of specimen tilt. (B) A schematic three-dimensional interpretation of the structure are represented (a, b and c).
Fig. 7 Reaction of bluetongue antibodies to recombinant baculovirus derived antigen using indirect ELISA: Recombinant AcBTV 10-6 infected cell extracts were adsorbed to the solid phase and examined using 1:100 to 1:12800 dilutions of sheep anti-BTV-2 serum (β e), or anti-BTV- 10 serum (o o), or anti-BTV-11 serum (Δ A), or anti-BTV-13 serum (Δ Δ), or anti-BTV-17 serum (G □), or with normal sheep serum (gg U).
Fig. 8 SDS-PAGE of purified NSI protein stained with Coomassie brilliant blue: AcBTV10-6 recombinant baculovirus infected cells were disrupted and tubules were recovered by sedimenting in sucrose gradient (10-50% w/v) centrifugation as described in Methods. The peak fractions containing NSl were pooled and subjected to SDS-PAGE analysis. The proteins recovered from unpurifϊed recombinant virus infected cells (1) are compared with NSl protein purified through sucrose gradient centrifugation (2).
- /S
Table 1. Amino acid composition of the predicted NSI protein of BTV-10
% of Mol. Ratio
7.4 77 5.7 3.6 2.9 7.0 4.7 5.9 2.5 7.0 7.6 4.2 4.2 4.7 3.6 4.5 4.2 2.3 5.1 4.9
Claims
- ή -
1. A process for producing a polypeptide comprising a bluetongue virus non-structural protein in antigenic form which comprises infecting susceptible insects or cultured insect cells with an expression vector having a DNA segment coding for said polypeptide.
2. A process according to Claim 1 wherein said DNA segment codes for bluetongue NSl protein.
3. A process according to* Claim 1 or Claim 2 wherein the polypeptide is produced in a morphological form resembling structures observed in bluetongue virus infected mammalian cells. . A process according to Claim 2 wherein said polypeptide is produced in the form of tubules.
5. A process according to any preceding claim wherein the expression vector comprises a recombinant baculovirus.
6. A recombinant baculovirus suitable for use in the process of any of Claims 1 to 5 comprising a DNA segment coding for a polypeptide comprising a bluetongue virus non-structural protein and a promoter capable of directing expression of said polypeptide in an infected insect or in infected insect cells.
7. A recombinant' baculovirus as claimed in Claim 6 wherein the promoter is the polyhedrin promoter.
8. A polypeptide produced by the process of any of Claims 1 to 5-
9. Use of a polypeptide as claimed in Claim 8 to diagnose bluetongue virus infection in mammals.
10. Use of a polypeptide as claimed in Claim 8 in the manufacture of a vaccine.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8819453.5 | 1988-08-16 | ||
GB888819453A GB8819453D0 (en) | 1988-08-16 | 1988-08-16 | Production of bluetongue virus non-structural proteins using baculovirus expression vector |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1990002186A1 true WO1990002186A1 (en) | 1990-03-08 |
Family
ID=10642209
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1989/000939 WO1990002186A1 (en) | 1988-08-16 | 1989-08-15 | Production of bluetongue virus non-structural proteins using a baculovirus expression vector |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0431038A1 (en) |
AU (1) | AU4198889A (en) |
GB (1) | GB8819453D0 (en) |
WO (1) | WO1990002186A1 (en) |
ZA (1) | ZA896202B (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026254A2 (en) * | 2000-09-27 | 2002-04-04 | The Uab Research Foundation | Non-replicative particulate vaccine delivery system and methods of making and using same |
WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
WO2010037062A1 (en) | 2008-09-26 | 2010-04-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
EP2327724A2 (en) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178435A2 (en) * | 1984-08-31 | 1986-04-23 | Research Corporation | cDNA probe for the detection of bluetongue virus |
EP0279661A2 (en) * | 1987-02-19 | 1988-08-24 | Oxford Virology Limited | Production of bluetongue virus antigens using a baculovirus expression vector |
-
1988
- 1988-08-16 GB GB888819453A patent/GB8819453D0/en active Pending
-
1989
- 1989-08-15 WO PCT/GB1989/000939 patent/WO1990002186A1/en not_active Application Discontinuation
- 1989-08-15 AU AU41988/89A patent/AU4198889A/en not_active Abandoned
- 1989-08-15 ZA ZA896202A patent/ZA896202B/en unknown
- 1989-08-15 EP EP89909839A patent/EP0431038A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0178435A2 (en) * | 1984-08-31 | 1986-04-23 | Research Corporation | cDNA probe for the detection of bluetongue virus |
EP0279661A2 (en) * | 1987-02-19 | 1988-08-24 | Oxford Virology Limited | Production of bluetongue virus antigens using a baculovirus expression vector |
Non-Patent Citations (6)
Title |
---|
Biological Abstracts, Vol. 84, 1987, (Philadelphia, PA, US) H. HUISMANS et al.: "A Comparison of Different Cloned Bluetongue Virus Genome Segments as Probes for the Detection of Virus-Specified RNA" *see Abstracts 52328 & Virology, 158(2): 373-380, 1987* * |
CHEMICAL ABSTRACTS, Vol. 106, No. 21, 25 May 1987, (Columbus, Ohio, US), S. INUMARU et al.: "Production and Characterization of the Neutralization Antigen VP2 of Bluetongue Virus Serotype 10 using a Baculovirus Expression Vector", see page 549* Abstract 174284t & Virology, 1987, 157(2), 472-9* * |
J. Gen. Virol. , Vol. 67, 1986 SGM (GB) M.A. PURDY et al.: "Nucleotide Sequence of cDNA Clones Encoding the Outer Capsid Protein, VP5, of Bluetongue Virus Serotype 10", pages 957-962 * |
J. Gen. Virol., Vol. 68, 1987, SGM (GB) S. INUMARU et al.: "Expression of Bluetongue Virus Group-Specific Antigen VP3 in Insect Cells by a Baculovirus Vector: its use for the Detection of Bluetongue Virus Antibodies" page 1627 * |
Journal of Virology, Vol. 62, November 1988 American Soc. for Microbiology (US) T. URAKAWA et al.: "Bluetongue Virus Tubules made in Insect Cells by Recombinant Baculoviruses: Expression of the NS1 Gene of Bluetongue Virus Serotype 10" pages 3919-3927 * |
Nucleic Acids Resaerch, Vol. 15, No. 17, 1987 IRL Press Ltd, Oxford, (GB) J. LEE et al.: "Complete Sequence of the NS1 Gene (M6 RNA) of Bluetongue Virus Serotype 10", page 7207 * |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026254A3 (en) * | 2000-09-27 | 2003-01-23 | Uab Research Foundation | Non-replicative particulate vaccine delivery system and methods of making and using same |
WO2002026254A2 (en) * | 2000-09-27 | 2002-04-04 | The Uab Research Foundation | Non-replicative particulate vaccine delivery system and methods of making and using same |
US8906676B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8097702B2 (en) | 2004-02-02 | 2012-01-17 | Ambrx, Inc. | Modified human interferon polypeptides with at least one non-naturally encoded amino acid and their uses |
US9260472B2 (en) | 2004-02-02 | 2016-02-16 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8907064B2 (en) | 2004-02-02 | 2014-12-09 | Ambrx, Inc. | Modified human four helical bundle polypeptides and their uses |
US8232371B2 (en) | 2004-02-02 | 2012-07-31 | Ambrx, Inc. | Modified human interferon polypeptides and their uses |
EP2327724A2 (en) | 2004-02-02 | 2011-06-01 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
US9175083B2 (en) | 2004-06-18 | 2015-11-03 | Ambrx, Inc. | Antigen-binding polypeptides and their uses |
EP2284191A2 (en) | 2004-12-22 | 2011-02-16 | Ambrx, Inc. | Process for the preparation of hGH |
US7816320B2 (en) | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
US7846689B2 (en) | 2004-12-22 | 2010-12-07 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7858344B2 (en) | 2004-12-22 | 2010-12-28 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7883866B2 (en) | 2004-12-22 | 2011-02-08 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US8143216B2 (en) | 2004-12-22 | 2012-03-27 | Ambrx, Inc. | Modified human growth hormone |
US7829310B2 (en) | 2004-12-22 | 2010-11-09 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7939496B2 (en) | 2004-12-22 | 2011-05-10 | Ambrx, Inc. | Modified human growth horomone polypeptides and their uses |
US7947473B2 (en) | 2004-12-22 | 2011-05-24 | Ambrx, Inc. | Methods for expression and purification of pegylated recombinant human growth hormone containing a non-naturally encoded keto amino acid |
US7838265B2 (en) | 2004-12-22 | 2010-11-23 | Ambrx, Inc. | Compositions of aminoacyl-tRNA synthetase and uses thereof |
US7959926B2 (en) | 2004-12-22 | 2011-06-14 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone mutants |
US7736872B2 (en) | 2004-12-22 | 2010-06-15 | Ambrx, Inc. | Compositions of aminoacyl-TRNA synthetase and uses thereof |
US8178108B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Methods for expression and purification of recombinant human growth hormone |
US8163695B2 (en) | 2004-12-22 | 2012-04-24 | Ambrx | Formulations of human growth hormone comprising a non-naturally encoded amino acid |
US8080391B2 (en) | 2004-12-22 | 2011-12-20 | Ambrx, Inc. | Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer |
EP2399893A2 (en) | 2004-12-22 | 2011-12-28 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8178494B2 (en) | 2004-12-22 | 2012-05-15 | Ambrx, Inc. | Modified human growth hormone formulations with an increased serum half-life |
WO2006069246A2 (en) | 2004-12-22 | 2006-06-29 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides |
US8093356B2 (en) | 2005-06-03 | 2012-01-10 | Ambrx, Inc. | Pegylated human interferon polypeptides |
US9488660B2 (en) | 2005-11-16 | 2016-11-08 | Ambrx, Inc. | Methods and compositions comprising non-natural amino acids |
US8053560B2 (en) | 2006-09-08 | 2011-11-08 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US8420792B2 (en) | 2006-09-08 | 2013-04-16 | Ambrx, Inc. | Suppressor tRNA transcription in vertebrate cells |
US9133495B2 (en) | 2006-09-08 | 2015-09-15 | Ambrx, Inc. | Hybrid suppressor tRNA for vertebrate cells |
US8022186B2 (en) | 2006-09-08 | 2011-09-20 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
WO2008030558A2 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
US7919591B2 (en) | 2006-09-08 | 2011-04-05 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US8618257B2 (en) | 2006-09-08 | 2013-12-31 | Ambrx, Inc. | Modified human plasma polypeptide or Fc scaffolds and their uses |
US9079971B2 (en) | 2007-03-30 | 2015-07-14 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US8012931B2 (en) | 2007-03-30 | 2011-09-06 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8383365B2 (en) | 2007-03-30 | 2013-02-26 | Ambrx, Inc. | Methods of making FGF-21 mutants comprising non-naturally encoded phenylalanine derivatives |
US10377805B2 (en) | 2007-03-30 | 2019-08-13 | Ambrx, Inc. | Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses |
US9517273B2 (en) | 2007-03-30 | 2016-12-13 | Ambrx, Inc. | Methods of treatment using modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US9975936B2 (en) | 2007-03-30 | 2018-05-22 | Ambrx, Inc. | Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids |
US11993637B2 (en) | 2007-03-30 | 2024-05-28 | Ambrx, Inc. | Modified FGF-21 polypeptides with non-naturally encoded amino acids |
US10961291B2 (en) | 2007-03-30 | 2021-03-30 | Ambrx, Inc. | Modified FGF-21 polypeptides and their uses |
US8114630B2 (en) | 2007-05-02 | 2012-02-14 | Ambrx, Inc. | Modified interferon beta polypeptides and their uses |
US8946148B2 (en) | 2007-11-20 | 2015-02-03 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
EP2930182A1 (en) | 2007-11-20 | 2015-10-14 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
WO2009067636A2 (en) | 2007-11-20 | 2009-05-28 | Ambrx, Inc. | Modified insulin polypeptides and their uses |
US9938333B2 (en) | 2008-02-08 | 2018-04-10 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
EP3103880A1 (en) | 2008-02-08 | 2016-12-14 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
EP3225248A1 (en) | 2008-07-23 | 2017-10-04 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
US10138283B2 (en) | 2008-07-23 | 2018-11-27 | Ambrx, Inc. | Modified bovine G-CSF polypeptides and their uses |
WO2010011735A2 (en) | 2008-07-23 | 2010-01-28 | Ambrx, Inc. | Modified bovine g-csf polypeptides and their uses |
US10428333B2 (en) | 2008-09-26 | 2019-10-01 | Ambrx Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US8278418B2 (en) | 2008-09-26 | 2012-10-02 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
US9156899B2 (en) | 2008-09-26 | 2015-10-13 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
US9121024B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
US8569233B2 (en) | 2008-09-26 | 2013-10-29 | Eli Lilly And Company | Modified animal erythropoietin polypeptides and their uses |
US9644014B2 (en) | 2008-09-26 | 2017-05-09 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
EP3216800A1 (en) | 2008-09-26 | 2017-09-13 | Ambrx, Inc. | Modified animal erythropoietin polypeptides and their uses |
US9121025B2 (en) | 2008-09-26 | 2015-09-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
WO2010037062A1 (en) | 2008-09-26 | 2010-04-01 | Ambrx, Inc. | Non-natural amino acid replication-dependent microorganisms and vaccines |
EP2805964A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
EP2805965A1 (en) | 2009-12-21 | 2014-11-26 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
US9962450B2 (en) | 2010-08-17 | 2018-05-08 | Ambrx, Inc. | Method of treating heart failure with modified relaxin polypeptides |
US9452222B2 (en) | 2010-08-17 | 2016-09-27 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
EP4302783A2 (en) | 2010-08-17 | 2024-01-10 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US11786578B2 (en) | 2010-08-17 | 2023-10-17 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US10253083B2 (en) | 2010-08-17 | 2019-04-09 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US11439710B2 (en) | 2010-08-17 | 2022-09-13 | Ambrx, Inc. | Nucleic acids encoding modified relaxin polypeptides |
US11311605B2 (en) | 2010-08-17 | 2022-04-26 | Ambrx, Inc. | Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides |
US8735539B2 (en) | 2010-08-17 | 2014-05-27 | Ambrx, Inc. | Relaxin polypeptides comprising non-naturally encoded amino acids |
WO2012024452A2 (en) | 2010-08-17 | 2012-02-23 | Ambrx, Inc. | Modified relaxin polypeptides and their uses |
US10702588B2 (en) | 2010-08-17 | 2020-07-07 | Ambrx, Inc. | Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain |
US10751391B2 (en) | 2010-08-17 | 2020-08-25 | Ambrx, Inc. | Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid |
US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
US11273202B2 (en) | 2010-09-23 | 2022-03-15 | Elanco Us Inc. | Formulations for bovine granulocyte colony stimulating factor and variants thereof |
US11248031B2 (en) | 2014-10-24 | 2022-02-15 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides |
US10377806B2 (en) | 2014-10-24 | 2019-08-13 | Bristol-Myers Squibb Company | Methods of treating diseases associated with fibrosis using modified FGF-21 polypeptides and uses thereof |
US10189883B2 (en) | 2014-10-24 | 2019-01-29 | Bristol-Myers Squibb Company | Therapeutic uses of modified FGF-21 polypeptides |
US9631004B2 (en) | 2014-10-24 | 2017-04-25 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US9434778B2 (en) | 2014-10-24 | 2016-09-06 | Bristol-Myers Squibb Company | Modified FGF-21 polypeptides comprising an internal deletion and uses thereof |
US11185570B2 (en) | 2017-02-08 | 2021-11-30 | Bristol-Myers Squibb Company | Method of treating cardiovascular disease and heart failure with modified relaxin polypeptides |
US11364281B2 (en) | 2017-02-08 | 2022-06-21 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and pharmaceutical compositions thereof |
US10266578B2 (en) | 2017-02-08 | 2019-04-23 | Bristol-Myers Squibb Company | Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof |
US12097242B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Treatment of fibrosis, cardiovascular disease and heart failure with modified relaxin polypeptides |
US12097241B2 (en) | 2017-02-08 | 2024-09-24 | Bristol-Myers Squibb Company | Methods of treating kidney failure, and/or improving or stablizing renal function using modified relaxin polypeptides |
Also Published As
Publication number | Publication date |
---|---|
AU4198889A (en) | 1990-03-23 |
GB8819453D0 (en) | 1988-09-21 |
EP0431038A1 (en) | 1991-06-12 |
ZA896202B (en) | 1990-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1990002186A1 (en) | Production of bluetongue virus non-structural proteins using a baculovirus expression vector | |
Urakawa et al. | Bluetongue virus tubules made in insect cells by recombinant baculoviruses: expression of the NS1 gene of bluetongue virus serotype 10 | |
Belyaev et al. | Development of baculovirus triple and quadruple expression vectors: co-expression of three or four bluetongue virus proteins and the synthesis of bluetongue virus-like particles in insect cells | |
French et al. | Synthesis of bluetongue virus (BTV) corelike particles by a recombinant baculovirus expressing the two major structural core proteins of BTV | |
DE3751092T2 (en) | Production and immunogenicity of rotavirus genes using a baculovirus expression system. | |
DE69223939T2 (en) | METHOD FOR PRODUCING SUB-UNIT VACCINE AGAINST DOG PARVOVIRUS AND RELATED VIRUSES | |
Roy et al. | Identification of bluetongue virus VP6 protein as a nucleic acid-binding protein and the localization of VP6 in virus-infected vertebrate cells | |
Le Blois et al. | Synthesis and characterization of chimeric particles between epizootic hemorrhagic disease virus and bluetongue virus: functional domains are conserved on the VP3 protein | |
DE69019359T2 (en) | HUMAN PARVOVIRUS B19 PROTEINS AND VIRUS-LIKE PARTICLES, THEIR PRODUCTION AND THEIR USE IN DIAGNOSTIC TESTS AND VACCINES. | |
JPH05292976A (en) | Mareks' disease virus vaccine | |
JPH0365191A (en) | Spheroidine isolated dna and recombinant insect pox virus expression vector | |
AP114A (en) | Production of bluetongue virus antigens using a baculovirus expression vector. | |
Taylor et al. | Transient expression and mutational analysis of the rotavirus intracellular receptor: the C-terminal methionine residue is essential for ligand binding | |
DE3382718T2 (en) | Peptides containing an immunogen location of the Sabin strain poliovirus. | |
KR100224331B1 (en) | Recombinant varicella-zoster virus and process for constructing same | |
US6379885B1 (en) | Human parvovirus B19 proteins and virus-like particles, their production and their use in diagnostic assays and vaccines | |
EP0284791B1 (en) | DNA and RNA molecules of the western-subtype TBE virus, polypeptides coded by these molecules and their use | |
JPH02501114A (en) | Expression vectors for protein synthesis and plasmid replicons and sequence cassettes used in such vector construction | |
Monastyrskaya et al. | Characterization and modification of the carboxy-terminal sequences of bluetongue virus type 10 NS1 protein in relation to tubule formation and location of an antigenic epitope in the vicinity of the carboxy terminus of the protein | |
AU667796B2 (en) | Production of antigens by self-assembly of polypeptide components | |
US5686270A (en) | Production of antigens by self-assembly of polypeptide components | |
Nel et al. | A comparison of different cloned genome segments of epizootic haemorrhagic disease virus as serogroup-specific probes | |
Brun et al. | The relationship of Piry virus to other vesiculoviruses: a re-evaluation based on the glycoprotein gene sequence | |
US5833995A (en) | Use of bluetongue virus proteins as vaccine components | |
TANAKA et al. | Synthesis of bluetongue virus chimeric VP3 molecules and their interactions with VP7 protein to assemble into virus core-like particles |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1989909839 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1989909839 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1989909839 Country of ref document: EP |